{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:46:15Z","timestamp":1773099975749,"version":"3.50.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,9]]},"DOI":"10.1093\/ajhp\/zxab132","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T03:06:34Z","timestamp":1616814394000},"page":"1270-1272","source":"Crossref","is-referenced-by-count":9,"title":["Transitioning from guideline approval to practical implementation of AUC-based monitoring of vancomycin"],"prefix":"10.1093","volume":"78","author":[{"given":"Christopher M","family":"Bland","sequence":"first","affiliation":[{"name":"University of Georgia College of Pharmacy Savannah, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney M","family":"Crosby","sequence":"additional","affiliation":[{"name":"University of Georgia College of Pharmacy Savannah, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin L","family":"Orvin","sequence":"additional","affiliation":[{"name":"St. Joseph\u2019s\/Candler Health System, Inc. Savannah, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Georgia College of Pharmacy Athens, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce M","family":"Jones","sequence":"additional","affiliation":[{"name":"St. Joseph\u2019s\/Candler Health System, Inc. Savannah, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"2021071005385478400_CIT0001","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm."},{"key":"2021071005385478400_CIT0002","doi-asserted-by":"crossref","first-page":"e01684-17","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"2021071005385478400_CIT0003","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2146\/ajhp180034","article-title":"Making the change to area under the curve\u2013based vancomycin dosing","volume":"75","author":"Heil","year":"2018","journal-title":"Am J Health-Syst Pharm."},{"key":"2021071005385478400_CIT0004","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/jac\/dkz167","article-title":"Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model","volume":"74","author":"Avedissian","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"2021071005385478400_CIT0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.japh.2020.02.025","article-title":"Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia","volume":"60","author":"Beccari","year":"2020","journal-title":"J Am Pharm Assoc (2003)."},{"key":"2021071005385478400_CIT0006","first-page":"ciaa1354","article-title":"Vancomycin advanced therapeutic drug monitoring: an exercise in futility or virtuous endeavor to improve drug efficacy and safety?","volume":"Sep 8","author":"Dilworth","year":"2020","journal-title":"Clin Infect Dis."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxab132\/36742813\/zxab132.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/14\/1270\/38891791\/zxab132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/14\/1270\/38891791\/zxab132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:40:21Z","timestamp":1671727221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/14\/1270\/6189763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":6,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,3,27]]},"published-print":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxab132","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,15]]},"published":{"date-parts":[[2021,3,27]]}}}